ASLAN Pharmaceuticals (ASLN)
(Delayed Data from NSDQ)
$0.41 USD
-0.01 (-2.10%)
Updated May 10, 2024 04:00 PM ET
After-Market: $0.42 +0.01 (2.19%) 7:58 PM ET
2-Buy of 5 2
F Value D Growth C Momentum F VGM
Price, Consensus and EPS Surprise
ASLN 0.41 -0.01(-2.10%)
Will ASLN be a Portfolio Killer in May?
Zacks Investment Research is releasing its prediction for ASLN based on the 1-3 month trading system that more than doubles the S&P 500.
About Price, Consensus and EPS Surprise
The Price, Consensus and EPS Surprise chart displays the company's stock price along with the consensus estimate and the EPS surprise. Zacks tracks individual sell-side analyst estimates and creates a consensus EPS estimates. The consensus estimate is the average of all the current estimates made available by brokerage analysts. Consensus estimates are more advantageous because they reduce the risk of any single analyst making an incorrect forecast. ZACKS CONSENSUS ESTIMATE = THE AVERAGE OF ALL CURRENT EPS ESTIMATES. EPS Surprise is the difference (expressed as a percentage) between the actual reported quarterly earnings per share (EPS) vs the estimated quarterly EPS. A company that reports $1.10 in actual quarterly EPS vs. $1.00 in estimated quarterly EPS would show a 10% positive EPS surprise. ((Actual EPS - Estimated EPS) / absolute Estimated EPS) *100 = EPS Surprise %.
Zacks News for ASLN
Are Medical Stocks Lagging ASLAN Pharmaceuticals (ASLN) This Year?
Is Aclaris Therapeutics (ACRS) Stock Outpacing Its Medical Peers This Year?
ASLN: What are Zacks experts saying now?
Zacks Private Portfolio Services
ASLAN (ASLN) Up 161% on Upbeat Initial Data From Eczema Study
Reasons to Add Acadia (ACAD) Stock to Your Portfolio Now
ASLAN (ASLN) Down 25% on Mixed Results From Skin Disease Study
Other News for ASLN
Piper Sandler Remains a Buy on Aslan Pharmaceuticals (ASLN)
ASLN Stock Earnings: ASLAN Pharma Beats EPS for Q1 2024
ASLAN Pharmaceuticals GAAP EPADS of -$1.29
ASLAN Pharmaceuticals Excels in Eblasakimab Trials
ASLAN Pharmaceuticals Reports First Quarter 2024 Financial Results and Provides Corporate Update